Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.
about
Multiparametric Magnetic Resonance Imaging of the Prostate: Repeatability of Volume and Apparent Diffusion Coefficient Quantification.Score 3 prostate lesions: a gray zone for PI-RADS v2.Comparison of quantitative apparent diffusion coefficient parameters with prostate imaging reporting and data system V2 assessment for detection of clinically significant peripheral zone prostate cancer.Knowledge, attitudes, and practices towards prostate cancer screening amongst men living in the southern Italian peninsula: the Prevention and Research in Oncology (PRO) non-profit Foundation experience.Serum metabolomics can predict the outcome of first systematic transrectal prostate biopsy in patients with PSA <10 ng/ml.Additional benefit of using a risk-based selection for prostate biopsy: an analysis of biopsy complications in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.Magnetic resonance imaging targeted transperineal prostate biopsy: a local anaesthetic approach.The Contemporary Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Prostate Cancer.Advances in Imaging in Prostate and Bladder Cancer.Multi-parametric MRI imaging of the prostate-implications for focal therapy.The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy.Diagnostic value of MRI-based PSA density in predicting transperineal sector-guided prostate biopsy outcomes.Focal therapy for prostate cancer: the technical challenges.From PROMIS to PRO-MRI in primary prostate cancer diagnosis.Most of patients with localized prostate cancer will be treated in the future? | Opinion: Yes.Most of patients with localized prostate cancer will be treated in the future? | Opinion: No.Update on Screening for Urological Malignancies.Potential of asphericity as a novel diagnostic parameter in the evaluation of patients with 68Ga-PSMA-HBED-CC PET-positive prostate cancer lesions.Diagnostic Accuracy of Magnetic Resonance Imaging (MRI) 5-Point Likert Scoring System Evaluated by The Result of MRI/Ultrasonography Image-fusion Targeted Biopsy of The Prostate.A prospective study of magnetic resonance imaging and ultrasonography (MRI/US)-fusion targeted biopsy and concurrent systematic transperineal biopsy with the average of 18-cores to detect clinically significant prostate cancer.Recommandations de l’Association des urologues du Canada sur le dépistage et le diagnostic précoce du cancer de la prostate.Suspicious findings on micro-ultrasound imaging and early detection of prostate cancer.Non-Invasive Prostate Cancer Characterization with Diffusion-Weighted MRI: Insight from In silico Studies of a Transgenic Mouse Model.A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial.Spatial Tracking of Targeted Prostate Biopsy Locations: Moving Towards Effective Focal Partial Prostate Gland Ablation with Improved Treatment Planning.Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer.Targeted versus systematic robot-assisted transperineal MRI-TRUS fusion prostate biopsy.Updates on the diagnosis and treatment of prostate cancer.Characteristics of PI-RADS 4 lesions within the prostatic peripheral zone: a retrospective diagnostic accuracy study evaluating 170 lesions.Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI.Engaging the primary care community to encourage appropriate prostate cancer screening.Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer.Ruling out clinically significant prostate cancer with negative multi-parametric MRI.3D T2-weighted imaging to shorten multiparametric prostate MRI protocols.Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters.HistoScanningTM to Detect and Characterize Prostate Cancer-a Review of Existing Literature.An update of pitfalls in prostate mpMRI: a practical approach through the lens of PI-RADS v. 2 guidelines.A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale.Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy-naïve men with suspicion of prostate cancer.Magnetic resonance imaging of the prostate and targeted biopsy, Comparison of PIRADS and Gleason grading.
P2860
Q30491569-AD5BBB25-5108-4B35-8F99-42317E8D40BEQ38598713-1AD5A951-C6F6-4857-B390-E1C8901BB7FBQ38608810-913458EA-07B7-4B27-A626-850151D32168Q38638510-90662083-E62B-4FF8-AA03-4188D3A755D3Q38646996-01513A12-E2F1-481C-BA17-2F82F187632EQ38789338-5D928E4E-8626-424E-A25C-4F17A2DF533AQ39191190-095CDD65-5847-459C-879C-0EFFDCD0CA49Q39356191-27550026-4ED3-4BAE-95FA-60188023EF5AQ39441078-4FAE86E0-B386-4CA4-B43C-8466628E29C4Q39446420-601E2C1C-190D-4E59-BEE9-9F13058523A9Q39464632-858ABC55-ACDE-4586-A317-88416C72D4F3Q40212899-F1FB4B27-0E2C-45C0-BAEE-0B550CC0CC5DQ41689116-57786127-8F29-4CF6-B567-5A68018D92C1Q42332347-4CAD67BC-BB95-4D86-9E1E-EDB31BA35A06Q42345804-9AD43CEA-650D-4D8D-8EBB-09EF308A4C1BQ42345805-69959203-534A-433A-A1A9-4D1931E512E9Q42649779-5FF5E1E5-CE1E-4A1E-8F67-299CE18C8366Q43119026-C2E06784-711A-45E1-AD7A-0DF6E2D2D0DCQ44688793-BAA70D6F-7FAA-4461-A915-D2F8B66B2D18Q47097032-DB580195-E7C1-45CE-B693-2826909C8ABFQ47123251-2851062D-C8E9-4ADF-A3D2-7B1F6DFF2ACBQ47125420-D6C5D6FA-C98C-42D6-AE6B-8BA8FFC149A3Q47139773-4AA96F7D-8144-46D6-B4B2-65D01105F54DQ47232656-E0151AB9-3A6C-4A45-A39A-C7D77CB750CBQ47289972-B7C490FD-A71F-4086-8536-F05D58F834B6Q47303003-7C87088B-B181-4E69-A201-DA5ED089AF35Q47357407-BF2005A1-D6BD-4191-B981-9C660CCD3D84Q47361793-86E2F702-197E-4799-974C-A0EA79CA9716Q47379407-55C56DC5-BB72-4B98-B1C3-AB414FE91D5AQ47393127-A7155689-FCB3-49D3-A216-7DE25D49D79BQ47561590-3EC083F8-80BE-4B71-AC8C-E916EE1CE8F4Q47573527-F4CA83FB-013A-4757-B6F6-8DF0A32A32FFQ47588633-B744B074-103C-4306-AAC1-5D09450FAE6EQ47603123-197DEAA7-87CC-408C-8202-0CBF9E34CAD7Q47725386-E156A72F-26F8-48F1-B1F3-9F4A58ED4979Q47731511-7ECD37DC-7877-461D-88F2-A7ACF1371963Q47732645-076FB3BE-CD2F-43AF-B96D-9A3DD1C4F020Q47759609-C468EBCB-3B5D-4EE6-BB54-0022CE468E00Q47811496-F2B39F11-A55C-4A1D-BBD7-C14D01A01925Q47838908-3CE40669-494D-4F20-8241-32311A25B7B7
P2860
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Diagnostic accuracy of multi-p ...... validating confirmatory study.
@en
type
label
Diagnostic accuracy of multi-p ...... validating confirmatory study.
@en
prefLabel
Diagnostic accuracy of multi-p ...... validating confirmatory study.
@en
P2093
P1433
P1476
Diagnostic accuracy of multi-p ...... validating confirmatory study.
@en
P2093
Ahmed El-Shater Bosaily
Alex Freeman
Alex P Kirkham
Chris Parker
Hashim U Ahmed
Katie Ward
Louise C Brown
Mahesh K Parmar
PROMIS study group
Rhian Gabe
P304
P356
10.1016/S0140-6736(16)32401-1
P407
P577
2017-01-19T00:00:00Z